Evotec (EVO) said Wednesday the company, alongside Yonsei University and biotech firm Zymedi, will receive a $4.5 million grant from the Korea Institute of Advanced Technology to fund the development of therapies to treat lung diseases.
The company said the project will focus on development of new anti-inflammatory and anti-fibrotic antibodies to treat diseases with unmet medical needs, including idiopathic pulmonary fibrosis and non-type 2 asthma.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。